Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Vanda: Q2 Earnings Snapshot AP - Wed Aug 5, 3:07PM CDT

Vanda: Q2 Earnings Snapshot

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results PR Newswire - Wed Aug 5, 3:01PM CDT

WASHINGTON , Aug. 5, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2026. 

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals: The Tradipitant Timeline Matters More Than the Fanapt Numbers Barchart - Tue Aug 4, 4:37PM CDT

Barchart Research What to Expect from VNDA Earnings VNDA Generated August 4, 2026 Current Price $5.33 EPS Estimate $$-0.50 Consensus Rating Moderate Buy Average Move 8.65% Vanda Pharmaceuticals: The Tradipitant...

VNDA : 5.09 (-4.50%)
Vanda's Pipeline Momentum Collides With a Shrinking Commercial Base Barchart - Wed Jul 29, 4:26PM CDT

Barchart Research What to Expect from VNDA Earnings VNDA Generated July 29, 2026 Current Price $5.05 EPS Estimate $$-0.50 Consensus Rating Moderate Buy Average Move 8.65% Vanda's Pipeline Momentum Collides...

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 PR Newswire - Wed Jul 29, 3:31PM CDT

Conference Call and Webcast to Follow

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe PR Newswire - Thu Jul 16, 3:30PM CDT

WASHINGTON , July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA)...

VNDA : 5.09 (-4.50%)
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment PR Newswire - Wed Jul 15, 3:30PM CDT

WASHINGTON , July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention...

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit PR Newswire - Fri Jul 10, 3:30PM CDT

WASHINGTON , July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind,...

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S PR Newswire - Tue Jul 7, 3:30PM CDT

WASHINGTON , July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation...

VNDA : 5.09 (-4.50%)
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis PR Newswire - Wed May 27, 6:00AM CDT

WASHINGTON , May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation...

VNDA : 5.09 (-4.50%)

Barchart Exclusives

This Dividend King Yields Over 4% and Trades Near Its 52-Week Lows, But Don’t Rush to Buy the Dip Barchart - Wed Aug 5, 6:30PM CDT
PepsiCo is trading near 52-week lows while rival Coca-Cola is near its 52-week highs. However, a dividend yield of over 4% and tepid valuations make PEP stock a buy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.